Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis

References

• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–659.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84:432–470.
   PubMed Web of Science ®Google Scholar
• Bagel J, Thibodeaux QG, Han G. Halobetasol propionate for the management of psoriasis. Cutis. 2020;105:92–96. E94.
   PubMed Web of Science ®Google Scholar
• Bryhali [package insert]. Bridgewater (NJ): Ortho Dermatologics; 2018.
   Google Scholar
• Weinstein GD, Koo JY, Krueger GG, et al., Tazarotene Cream Clinical Study Group. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48:760–767.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Stein Gold L, Del Rosso JQ, et al. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. J Dermatolog Treat. 2019.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39:590–596.
   PubMed Web of Science ®Google Scholar
• Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol. 2001;40:210–212.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Kircik L, Lin T, et al. Halobetasol 0.01%/tazarotene 0.045% fixed-combination lotion in the treatment of plaque psoriasis: sensitization and irritation potential. J Clin Aesthet Dermatol. 2019;12:11–15.
   PubMedGoogle Scholar
• Stein Gold L, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79:287–293.
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Weiss J, Tanghetti EA, et al. Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies. J Drugs Dermatol. 2018;17:855–861.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Stein Gold L, Papp K, et al. Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. J Eur Acad Dermatol Venereol. 2021.
   Web of Science ®Google Scholar
• Lebwohl MG, Sugarman JL, Gold LS, et al. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80:282–285.
   PubMed Web of Science ®Google Scholar
• Duobrii [package insert]. Bridgewater (NJ): Ortho Dermatologics; 2020.
   Google Scholar
• Korman NJ, Zhao Y, Roberts J, et al. Impact of psoriasis flare and remission on quality of life and work productivity: a real-world study in the USA. Dermatol Online J. 2016;22:13030/qt4vb7q7rr.
   Google Scholar
• [Data on file]. Bridgewater (NJ): Ortho Dermatologics; 2021.
   Google Scholar
• Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol. 2014;71:633–641.
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Gold LS, Lebwohl MG, et al. A phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis. J Drugs Dermatol. 2017;16:197–204.
   PubMed Web of Science ®Google Scholar
• Svendsen MT, Feldman SR, Tiedemann SN, et al. Psoriasis patient preferences for topical drugs: a systematic review. J Dermatolog Treat. 2019.
   Google Scholar
• Thiboutot D, Del Rosso JQ. Acne vulgaris and the epidermal barrier. J Clin Aesthet Dermatol. 2013;6:18–24.
   PubMedGoogle Scholar
• Del Rosso JQ, Cash K. Topical corticosteroid application and the structural and functional integrity of the epidermal barrier. J Clin Aesthet Dermatol. 2013;6:20–27.
   Google Scholar
• Segaert S, Calzavara-Pinton P, de la Cueva P, et al. Long-term topical management of psoriasis: the road ahead. J Dermatolog Treat. 2020.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Kircik L, Lacour JP, et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2020.
   Web of Science ®Google Scholar
• Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol. 1997;37:S12–S17.
   PubMed Web of Science ®Google Scholar
• Tanghetti E, Lebwohl M, Stein Gold L. Tazarotene revisited: safety and efficacy in plaque psoriasis and its emerging role in treatment strategy. J Drugs Dermatol. 2018;17:1280–1287.
   Web of Science ®Google Scholar